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Background: High-density lipoprotein (HDL) is associated with the incidence of metabolic syndrome (MetS). It is
unclear whether subjects with different HDL levels develop different components of MetS over time. Our study
aimed to determine what MetS components tend to emerge and change relative to different levels of HDL.
Methods: During the period 2007 to 2012, 4,905 adults in Tongren and Xiaotangshan Hospitals in Beijing were
included with no MetS, self-reported type 2 diabetes, or cardiovascular disease at baseline. An association rule was
used to determine the changes of MetS components over time.
Results: The incidence of MetS at follow-up was 3.40% for men and 1.50% for women in the high-normal HDL
group; 6.65% and 4.55%, respectively, in the normal HDL group; and 11.05% and 6.45%, respectively, in the low HDL
group. The most common transition was from healthy to healthy in normal-high or normal HDL groups (47.2% to
63.8%), whereas 11.7% to 39.9% of subjects with low HDL returned to healthy status or stayed unchanged in the
low HDL group. The most common new-onset components were elevated blood pressure (9.2 to 10.0%), elevated
high-density lipoprotein (5.5 to 11.0%), and raised fasting glucose (5.4 to 5.5%) in the groups with normal-high or
normal HDL.
Conclusions: The incidence of MetS increased in parallel with the decrease in HDL. Adults with a low HDL level
were more susceptible to developing MetS over time. Low HDL seemed to be a pre-existing phase of MetS and
may be a crucial status for MetS prevention.
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Metabolic syndrome (MetS) is a complicated medical
condition that includes five components: high plasma
glucose, high triglycerides, low high-density lipoprotein
cholesterol, high blood pressure, and abdominal obesity.
MetS is associated with an increased risk of the develop-
ment of cardiovascular disorders worldwide. Patients with
MetS have a two-fold greater relative risk for cardiovascu-
lar disease (CVD), a five-fold greater risk for type 2
diabetes mellitus (DM), a 2.2-fold greater risk for stroke,* Correspondence: guoxiuh@ccmu.edu.cn
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unless otherwise stated.and a 2.6-fold greater risk for chronic kidney disease [1-3].
A meta-analysis of 172,573 individuals demonstrated a
significantly higher risk of cardiovascular events associated
with MetS [4]. Lipid abnormalities, including low high-
density lipoprotein (HDL), in MetS may contribute sub-
stantially to these high cardiovascular risks [5].
It is not yet clear whether or not MetS has a single
cause, although it is known that insulin resistance is a
major underlying cause of MetS [6-8]. HDL has been
shown to be a key component in the prediction of CVD
risk and may trigger the pathogenesis of MetS [9]. A
cross-sectional study indicated that the HDL sub-class
ratio is strongly associated with HDL, insulin resistance,
as well as other MetS components in Japanese individuals
[10]. However, there have been few cohort studiess is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dominantly, and how the status of each component
changes over time [11-13]. These factors may hamper the
adequacy of management among individuals with MetS.
Our previous study revealed that people with optimal and
normal blood pressure were less susceptible to developing
MetS over a five year period, whereas abnormal blood
pressure seemed to be a pre-existing phase of MetS [14].
Multiple statistical methods, such as logistical regres-
sion, Cox proportional hazards regression model, a net-
work approach, latent transition, and factor analysis were
applied in the previous research [8,9,11-13]. However,
these methods can not deal with independent variables
that are correlated with each other. Thus association rule
mining (ARM), which is a popular data mining method
designed to identify groups of variables that are strongly
correlated with each other, or with respect to a specific
target variable, was used in the present study [15].
The purposes of this study were to investigate: 1)
whether or not there is a correlation between the level
of HDL and the incidence of MetS; 2) which compo-
nents tend to develop at each level of HDL; and 3) how
these components change with time.
Methods
Survey methodology
Subjects’ health records from routine physical check-ups
have been computerised since 2007 at Beijing Tongren
and Xiaotangshan Hospitals. We selected the records of
adult visitors who had a physical check-up, using entries
in 2007/2008 as the baseline, and 2011/2012 as the end
point. In total, 6,888 people who had check-up records
at both baseline and the follow-up were enrolled. Firstly,
438 people with any medical history of stroke, cerebral
infarction, myocardial infarction, or coronary heart dis-
ease, or in use of any hypoglycaemic, anti-dislipidemic,
or anti-hypertensive treatments were excluded. Secondly,
13 people aged less than 20 years and 991 people aged
over 65 years were excluded. Lastly, 538 subjects who
had MetS at baseline were ruled out. The final cohort
was composed of 4,905 subjects.
Measurements and laboratory tests
The participants underwent routine physical examina-
tions including measurements of weight, height, blood
pressure (BP), and analyses of blood biochemistry pa-
rameters. Height and body weight were measured in the
upright position to the nearest of 0.5 cm and 0.1 kg, re-
spectively. Electronic sphygmomanometers were used by
a trained nurse to measure the BP of each subject in the
sitting position after a 10-minute rest period. During the
30 min preceding the measurements, the subjects were
required to refrain from smoking or consuming caffeine
[16]. The readings of systolic blood pressure (SBP) anddiastolic blood pressure (DBP) were recorded, when the
second measurement was in an extent of 5 mmHg. Three
systolic and diastolic blood pressures were recorded, with
an interval of at least 1 minute between readings, and the
average of the last two measurements was used for data
analysis [16].
Blood samples were collected from an antecubital vein
in the morning after an overnight fasting period and
placed in tubes containing EDTA. The samples were ana-
lysed immediately after pre-treatment or stored at -80°C
in the ISO 15189 accredited medical laboratories of the
hospital for further analysis. Serum HDL concentration
was measured photometrically (Hitachi 704; Roche,
Mannheim, Germany), and TG and FPG concentrations
were determined enzymatically (Hitachi 717; Roche Diag-
nostics). All analyses were performed in accordance with
the manufacturer’s recommendations. The intra- and
inter-assay coefficients of variation for all laboratory tests
were under 5%.
Diagnosis of metabolic syndrome
Diagnostic criteria for the assessment of MetS compo-
nents were determined according to the Joint Interim
Statement Criteria [17]. Body mass index (BMI) was
regarded as a substitute for the component of obesity,
which was strongly correlated with waist circumference
(WC) in patients with MetS [18], as WC was not obtained.
The parameters used were as follows:
Overweight: 25 ≤ BMI < 30 kg/m2; obese: BMI ≥
30 kg/m2 [19];
 Raised TG level (drug treatment for raised
triglyceride level is an alternative indicator) ≥
150 mg/dL (1.7 mmol/L) [17];
 Reduced HDL level (drug treatment for reduced
HDL level is an alternative indicator): < 40 mg/dL
(1.0 mmol/L) in men; < 50 mg/dL (1.3 mmol/L) in
women [17];
 Raised BP (anti-hypertensive drug treatment in a
patient with a history of hypertension is an
alternative indicator ): systolic pressure ≥ 130
and/or diastolic ≥85 mm Hg [17];
 Raised FPG level (drug treatment with raised
glucose is an alternative indicator) ≥ 100 mg/dL
(5.6 mmol/L) [17];
 Participants fulfilling at least three out of these five
components were diagnosed as having MetS.
Association rule mining (ARM)
ARM, also known as market basket analysis (MBA), is a
popular data mining method designed to identify groups
of variables with respect to a specific target variable [15].
The strength of this method is that ARM measures the
support and confidence, as explained below. The support
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status to another status in all possible transitions, and
the confidence rate represents the number of cases tran-
sitioned within a certain status. In this study, support
rate and confidence rate were used to evaluate which
were the relatively frequent transition patterns and
which status increased most, respectively. More details
on the a priori algorithm underpinning ARM are avail-
able elsewhere [20-22].Layered approach for high-density lipoprotein levels at
baseline
HDL at baseline was categorised into two sub-groups ac-
cording to the Joint Scientific Statement of MetS [17]. To
avoid the overlap of “high-normal HDL” and “normal
HDL” in the Joint Scientific Statement criteria, we defined
high-normal HDL as HDL ≥ 60 mg/dL; normal HDL as
40 mg/dL ≤HDL < 60 mg/dL for men and 50 mg/dL ≤
HDL < 60 mg/dL for women; low HDL as HDL < 40 mg/
dL for men and HDL < 40 mg/dL for women.Statistical analysis
Categorical data are presented as percentages, and con-
tinuous data as mean plus standard deviation (SD). The
five components’ statuses were analysed at baseline and
follow-up. We performed ARM to analyse the changes in
each MetS component or combinations thereof during the
five-year period of this cohort study. As the subjects at
baseline were people with two or fewer MetS components,
there were 16 (i.e. C05 þ C15 þ C25 ) possible statuses at
baseline, with 32 (i.e. 25) possible statuses at follow-up.
Theoretically there were 512 (i.e. 16 × 32) possible transi-
tions between statuses from baseline to follow-up. The
data are presented as transitions of statuses that changed
from one risk factor to another, with “healthy” defined as
being that state free of MetS components.
A few values from biochemical sera were missing, thus
a multiple imputation (MI) was performed to impute the
missing information. According to the data distribution,
the Markov chain Monte Carlo (MCMC) method was
chosen to avoid the loss of generality. All analyses were
conducted using SAS software package (Version 9.2;
SAS Institute, Chicago, IL, USA). A 2-sided α of 0.05
was considered statistically significant. Bonferroni ad-
justment of critical p-values was adopted when perform-
ing multiple comparisons.Ethics statement
This study was approved by the Ethics Committee of the
Capital Medical University of China, Beijing, and performed
in accordance with the principles of the Declaration of
Helsinki (Reference No. 2013SY26).Consent
Written informed consent was obtained from each patient
for publication of this report and any accompanying
images.
Results
At baseline, of the 4,905 subjects, 45.3% were men with
a median age of 40.0 years (41.2 ± 11.0), while 54.7%
were women with a median age of 42 years (41.7 ± 10.2).
The follow-up interval was 4.78 ± 0.41 years for men and
4.81 ± 0.39 years for women, respectively. The baseline
characteristics are summarised in Table 1.
The components of MetS in the population at baseline
and follow-up were grouped by HDL level at baseline
(Tables 2, 3, 4 and 5). Subjects were divided into two age
groups (20 to 44 (young) and 45 to 65 (old)). The inci-
dence of MetS at follow-up was analysed by gender and
HDL level at baseline (Figures 1 and 2). Young men with
high-normal and normal HDL levels had a higher inci-
dence of MetS compared with women in the same groups
(2.57% versus 0.77%, and 5.95% versus 3.45%, respectively).
The numbers of young men and young women were
almost the same in the low HDL group (11.93% versus
10.17%). Whereas the numbers of old men and old
women were almost the same in the high-normal, normal,
and low HDL groups (4.55% versus 2.56%, 7.77% versus
6.05%, and 9.52% versus 8.00%, respectively).
The five most common transitions in each sub-group
were identified (Figure 3). As the sample size was too
small after grouping by age, the association rule was ap-
plied without sub-stratification of age. The support rate
of transitions (defined as the percentage changing from
initial status to another status via all possible transitions)
was examined in the period 2007/2008 to 2011/2012 in
the different sub-groups at baseline. For visual simplicity,
the five most commonly observed transitions are shown in
the relevant parts of Figure 3. The most common transi-
tion in both genders with normal-high and normal HDL
was “healthy” to “healthy”, whereas for the low HDL group,
the main transition was from “low HDL” to “healthy”. The
rates of transition are shown for each gender and HDL
group. The confidence rate represents how many cases
transitioned within a certain status. For example, 470 males
were initially healthy at baseline, and 280 (60.74%) of these
stayed healthy, while 54 (11.71%) transitioned to hyperten-
sion at the end of the observation period.
Discussion
This cohort study, comprising 4,905 subjects in Beijing
Tongren and Beijing Xiaotangshan Hospitals, focused on
investigating how the incidence of MetS changed relative
to HDL level and which MetS components tend to
emerge and change during the 5-year follow-up period.
Our study identified that the lower the HDL at baseline,
Table 1 The baseline characteristics of 20 to 65 years old subjects (n = 4 905)
Variables Total Men Women t value P value
N 4905 2222 2683 - -
Age (years) 41.5 ± 10.6 41.2 ± 11.0 41.7 ± 10.2 1.41 0.1582a
HDL (mmol/L) 22.6 ± 2.6 1.4 ± 0.3 1.6 ± 0.3 36.04 <0.0001a
SBP (mmHg) 108.2 ± 10.2 111.1 ± 9.0 105.7 ± 10.4 -19.44 <0.0001a
DBP (mmHg) 71.4 ± 7.2 73.5 ± 6.4 69.7 ± 7.4 -19.10 <0.0001a
TG (mmol/L) 4.9 ± 0.4 1.0 ± 0.3 0.8 ± 0.3 -20.62 <0.0001a
FPG (mmol/L) 0.9 ± 0.3 4.9 ± 0.4 4.9 ± 0.4 -2.57 0.0103a
BMI (kg/m2) 1.5 ± 0.3 23.5 ± 2.5 21.8 ± 2.5 -22.95 <0.0001a
Elevated HDL (%) 281(5.73) 172(7.74) 109 (4.06) 30.4467 <0.0001b
Elevated BP (%) 42(0.86) 24(1.08) 18(0.67) 2.3975 0.1215b
Elevated TG (%) 20(0.41) 13(0.59) 7(0.26) 3.1450 0.0762b
Elevated FPG (%) 19(0.39) 10(0.45) 9(0.34) 0.4137 0.5201b
Elevated BMI (%) 17(0.35) 11(0.50) 6(0.22) 2.5924 0.1074b
MetS metabolic syndrome, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, TG triglycerides.
aDetermined by two-sample t test.
bDetermined by χ2 test.
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that women with different levels of HDL would develop
different combinations of MetS components. On analys-
ing the change in MetS components, we identified that
those women with low HDL tended to have elevated
blood pressure as the most common additional MetS
component, while those women with higher HDL
tended to have elevated HDL as the most common new-
onset MetS component. Men tended to have elevated
blood pressure as the most common additional and
new-onset MetS component.
The HDL of people with normal-high and normal
high-density lipoprotein at baseline tended to decrease
with time, while the HDL increased in those subjects
with low high-density lipoprotein, according to Tables 2,
3, 4 and 5. Subjects with low high-density lipoprotein
may be alert to their health as health education and pro-
motion programmes are available through various media
in Beijing, possible actions on exercise and diet could beTable 2 The profile of MetS components in men aged 20 to 4
baseline (n = 1 356)
Variable High-normal HDL (n = 272) Normal HDL
Baseline Follow-up P-value Baseline
HDL (mmol/L) 1.75 ± 0.20 1.46 ± 0.30 <0.0001 1.27 ± 0.13
SBP (mmHg) 110.18 ± 9.38 116.44 ± 11.63 <0.0001 110.76 ± 8.81
DBP (mmHg) 72.62 ± 6.48 71.65 ± 8.95 0.0824 72.91 ± 6.50
TG (mmol/L) 0.89 ± 0.31 1.19 ± 0.77 <0.0001 1.00 ± 0.34
FPG (mmol/L) 4.86 ± 0.47 5.01 ± 0.42 <0.0001 4.87 ± 0.40
BMI (kg/m2) 22.19 ± 2.59 23.29 ± 2.93 <0.0001 23.44 ± 2.46
HDL high density lipoprotein, SBP systolic blood pressure, DBP diastolic blood press
BMI body mass index. P-value is based on paired t-test.intentionally or unintentionally taken, therefore their
HDL is controlled or even higher.
An association between low HDL and MetS has been
reported as the most prominent new onset MetS com-
ponent, or even serves as a key component of predicting
cardiovascular and diabetes risk [9,13,23]. Several studies
with structural equation modelling showed that low
HDL might play both a direct and indirect role in the
progression of MetS [24-26]. However, physiologically, it
is not easy to connect low HDL with MetS. In the
present study, we found that people with high-normal
and normal HDL tended to have a relatively lower inci-
dence of MetS after five years when compared with
people with low HDL, and were less susceptible to de-
veloping the disorder. Most subjects who started off as
healthy remained healthy, similar to a previous study
amongst a German population [13]. However, lowered
HDL tended to be the first risk factor of MetS for people
with normal HDL, which is roughly confirmed in4 of different high density lipoprotein group at
(n = 975) Low HDL (n = 109)
Follow-up P-value Baseline Follow-up P-value
1.22 ± 0.24 <0.0001 0.98 ± 0.08 1.12 ± 0.21 <0.0001
117.82 ± 12.11 <0.0001 110.50 ± 8.09 121.48 ± 13.67 <0.0001
72.67 ± 9.07 0.4203 72.63 ± 6.05 74.37 ± 10.86 0.0836
1.35 ± 0.76 <0.0001 1.12 ± 0.38 1.61 ± 0.86 <0.0001
5.10 ± 0.48 <0.0001 4.78 ± 0.49 5.16 ± 0.64 <0.0001
24.39 ± 2.66 <0.0001 24.07 ± 2.43 25.38 ± 2.65 <0.0001
ure, TG triglycerides, FPG fasting plasma glucose.
Table 3 The profile of MetS components in men aged 45 to 65 of different high density lipoprotein group at
baseline (n = 866)
Variable High-normal HDL (n = 198) Normal HDL (n = 605) Low HDL (n = 63)
Baseline Follow-up P-value Baseline Follow-up P-value Baseline Follow-up P-value
HDL (mmol/L) 1.76 ± 0.22 1.51 ± 0.34 <0.0001 1.28 ± 0.14 1.27 ± 0.26 0.1199 0.98 ± 0.11 1.17 ± 0.31 <0.0001
SBP (mmHg) 111.99 ± 9.68 119.40 ± 13.96 <0.0001 111.90 ± 8.98 120.90 ± 15.08 <0.0001 111.92 ± 9.08 120.36 ± 13.02 <0.0001
DBP (mmHg) 74.14 ± 6.36 73.40 ± 9.74 0.3292 74.64 ± 6.21 75.01 ± 10.39 0.3860 74.04 ± 6.62 76.16 ± 9.92 0.1110
TG (mmol/L) 1.01 ± 0.34 1.27 ± 0.85 <0.0001 1.11 ± 0.30 1.32 ± 0.58 <0.0001 1.14 ± 0.37 1.35 ± 0.54 0.0020
FPG (mmol/L) 4.97 ± 0.38 5.21 ± 0.51 <0.0001 4.95 ± 0.39 5.26 ± 0.72 <0.0001 4.70 ± 0.52 5.21 ± 0.60 <0.0001
BMI (kg/m2) 23.18 ± 2.52 23.59 ± 2.67 0.0024 23.96 ± 2.27 24.33 ± 2.48 <0.0001 24.29 ± 2.17 24.69 ± 2.31 0.0810
HDL high density lipoprotein, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglycerides, FPG fasting plasma glucose.
BMI body mass index. P-value is based on paired t-test.
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low HDL returned to “healthy”, while 12% continued to
remain in the same condition. Low HDL-C level has been
found to be independently and significantly related to
myocardial infarction or stroke in patients with MetS, thus
multi-factor treatment strategies, including strict life style
change, should be made to improve dyslipidemia in MetS
and decrease the residual risk for CVD in MetS [5,27].
The components of MetS tended to cluster in a way
which varied from one population to another [13,28]. In
our study, people with low HDL tended to have raised
blood pressure as a secondary risk factor. This is roughly
consistent with other studies, which found that elevated
blood pressure was the second most important compo-
nent of MetS and people with MetS tended to have
hypertension [14,23]. Low HDL seemed to be related to
each of the other four components. It is mainly a conse-
quence of systemic low-grade inflammation and apo A-I
dysfunction. In addition to the five components of MetS,
pro-thrombotic and pro-inflammatory states are essen-
tial features based on the evidence of impaired function
of HDL and apo A-I particles are discernible by bio-
logical evidence of functional defectiveness via outcomes
studies and/or correlations with inflammatory and anti-
inflammatory biomarkers [29]. The aggregation to lipo-
protein (Lp) (a) of apo A-I underlies HDL dysfunction,Table 4 The profile of MetS components group in women age
baseline (n = 1 595)
Variable High-normal HDL (n = 907) Normal HDL
Baseline Follow-up P-value Baseline
HDL (mmol/L) 1.83 ± 0.23 1.65 ± 0.33 <0.0001 1.41 ± 0.08
SBP (mmHg) 108.65 ± 10.21 108.83 ± 11.96 <0.0001 108.30 ± 10.32
DBP (mmHg) 71.51 ± 7.10 67.65 ± 8.41 0.0460 71.47 ± 7.39
TG (mmol/L) 0.91 ± 0.31 0.87 ± 0.41 <0.0001 1.00 ± 0.32
FPG (mmol/L) 4.89 ± 0.35 5.00 ± 0.45 <0.0001 4.88 ± 0.36
BMI (kg/m2) 22.47 ± 2.44 21.54 ± 2.68 <0.0001 23.02 ± 2.33
HDL high density lipoprotein, SBP systolic blood pressure, DBP diastolic blood press
BMI body mass index. P-value is based on paired t-test.and is an independent risk factor of magnitude similar
to conventional components of MetS [30]. Several stud-
ies showed that the steep increase in dyslipidemia could
be the reason for the growing prevalence of diabetes and
vice versa [23,31]. Dyslipidemia in patients with MetS
may be caused by a combination of increased catabolism
of HDL-apo A-I particles, overproduction of very LDL
apo B, and decreased catabolism of apo B containing
particles: these abnormalities may be consequences of
insulin resistance [32]. An important link between obes-
ity, the metabolic syndrome, and dyslipidemia, seems to
be the development of insulin resistance in peripheral
tissues leading to an enhanced hepatic flux of fatty acids
from dietary sources, intravascular lipolysis, and from
adipose tissue resistant to the antilipolytic effects of
insulin [32]. Previous reports indicated that pro-
inflammatory state and oxidative stress are crucial for
evaluating cardiometabolic risk. Factors such as creatinine,
platelet-activating factor acetyl hydrolase, thyroid stimu-
lating hormone, acetylation-stimulating protein, asymmet-
ric dimethylarginine, and serum lipoprotein (Lp) (a) are
key to triggering systemic low-grade inflammation and
enhanced autoimmune reactions, which may induce low
HDL and metabolic syndrome [33].
In most circumstances, “healthy” was the predominant
status, and subjects with a single MetS componentd 20 to 44 of different high density lipoprotein at
(n = 629) Low HDL (n = 59)
Follow-up P-value Baseline Follow-up P-value
1.40 ± 0.25 0.0576 1.13 ± 0.14 1.40 ± 0.33 <0.0001
110.07 ± 13.05 <0.0001 110.03 ± 10.08 112.75 ± 14.99 0.0007
67.95 ± 9.51 0.0813 72.81 ± 7.39 70.97 ± 9.84 0.1093
0.99 ± 0.48 <0.0001 0.90 ± 0.31 1.17 ± 1.03 0.0455
5.02 ± 0.42 <0.0001 4.79 ± 0.39 4.99 ± 0.41 0.0001
22.18 ± 2.83 <0.0001 23.53 ± 2.43 22.42 ± 2.81 0.0465
ure, TG triglycerides, FPG fasting plasma glucose.
Table 5 The profile of MetS components in women aged 45 to 65 of different high density lipoprotein group at
baseline (n = 1 088)
Variable High-normal HDL (n = 625) Normal HDL (n = 413) Low HDL (n = 50)
Baseline Follow-up P-value Baseline Follow-up P-value Baseline Follow-up P-value
HDL (mmol/L) 1.76 ± 0.22 1.69 ± 0.32 <0.0001 1.28 ± 0.14 1.46 ± 0.29 0.0003 0.98 ± 0.11 1.58 ± 0.27 <0.0001
SBP (mmHg) 111.88 ± 9.68 116.32 ± 15.01 <0.0001 111.90 ± 8.98 118.10 ± 15.19 <0.0001 111.92 ± 9.08 119.96 ± 14.08 <0.0001
DBP (mmHg) 74.14 ± 6.36 71.52 ± 9.77 0.9928 74.64 ± 6.21 72.79 ± 9.66 0.0064 74.04 ± 6.62 72.86 ± 10.70 0.9747
TG (mmol/L) 1.01 ± 0.34 1.14 ± 0.57 <0.0001 1.11 ± 0.30 1.21 ± 0.53 <0.0001 1.14 ± 0.37 1.24 ± 0.58 <0.0001
FPG (mmol/L) 4.97 ± 0.38 5.10 ± 0.46 <0.0001 4.95 ± 0.39 5.16 ± 0.50 <0.0001 4.70 ± 0.52 5.19 ± 0.49 <0.0001
BMI (kg/m2) 23.18 ± 2.52 22.95 ± 2.76 <0.0001 23.96 ± 2.27 23.34 ± 2.49 0.0008 24.29 ± 2.17 23.50 ± 2.79 0.9406
HDL high density lipoprotein, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglycerides, FPG fasting plasma glucose.
BMI body mass index. P-value is based on paired t-test.
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to be a crucial status for MetS prevention. Since dyslipid-
emia has low rates of awareness, treatment, and control
among Chinese adults, it is an important preventable risk
factor for MetS and CVD events [34].
The strengths of this study were that it was a longitu-
dinal study over five years in a Chinese population with
data subject to relatively good quality control. There
were some limitations to this study. The first limitation
of this study is the relatively small sample that might not
be sufficiently representative of the general adult popula-
tion and the demographics and referral source may limit
the generalisation of the results. Further studies using the
general population would be desirable. Secondly, informa-
tion about lifestyles was not available, but lifestyle vari-
ables will be included in further studies. The third
limitation is the lack of WC measurements as an indicator
of central obesity. However, BMI > 30 kg/m2 was used asFigure 1 The accumulated incidence of MetS in subjects aged 20-44, strat
high-normal HDL group of same gender using χ2 test, P < 0.025. #Comparea substitute for obesity [19]. Several studies have indicated
that two measures of BMI and WC are closely correlated
[18,35]. Most individuals with an abnormal BMI also have
an abnormal WC.Conclusions
The incidence of MetS increases with the reduction of
HDL over time. People with high-normal and normal
HDL were less susceptible than people with higher HDL
to developing MetS. Although most cases in the normal
HDL group stayed “healthy”, they tended to have de-
creased HDL as their initial sign of MetS. Low HDL was
a crucial status for MetS prevention as some of the cases
were able to return to “healthy”. In the low HDL group,
elevated blood pressure was a secondary risk factor.
More effective risk mitigation strategies are needed for
people with low HDL to prevent those developing MetS.ified by gender and high-density lipoprotein level. *Compared with
d with male counterpart using χ2 test, P < 0.05.
Figure 2 The accumulated incidence of MetS in subjects aged 45-65, stratified by gender and high-density lipoprotein level. *Compared with
high-normal HDL group of same gender using χ2 test, P < 0.025.
Figure 3 The support and confidence rate of the top five transitions in all subjects from 2007/2008 to 2011/2012 stratified by sex and high-density
lipoprotein groups. (A) in high-normal HDL group of males; (B) in normal HDL group of males; (C) in low HDL group of males; (D) in high-normal HDL
group of females; (E) in normal HDL group of females; (F) in low HDL group of females. Abbreviations: H, health, with the absence of any MetS
components; BP, high blood pressure; TG, raised triglycerides level; GLU, high fasting plasma glucose; HDL, increased high-density lipoprotein level.
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